Renal Cell Carcinoma Clear Cell Variant with Chromophobe Differentiation - A Rare Case Presentation

Tanvi Bhardwaj #, K. M. Hiwale † and Sunita Vagha ‡

# Department of Pathology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India.

† Professor, HOD

‡ M.D. Pathology Resident (1st year),

*Corresponding author: E-mail: tanvithwari.491@gmail.com;

ABSTRACT

Renal Cell Carcinoma (RCC) is a diverse growth of various histological cell forms, as well as genetic, biological, and behavioral variations, accounting for around 2%-4% of all genitourinary cancers worldwide and having the highest mortality rate. RCC is a rare symptom that occurs from the lower pole of the left kidney. Histopathological testing is critical for diagnosis, staging, and treatment evaluation. As a consequence, proper surgical and pathological correlation is critical for the diagnosis of such an unusually presented RCC. As a result, various RCC variants should be considered for proper diagnosis. We are here presenting a case of a woman aged 44-year-old, complaining for two months about a lump in her abdomen. Pain in the left lumbar area was noticed, which was progressive and accompanied by hematuria. The post-nephrectomy specimen was sent for histopathological analysis, and RCC was found (Clear Cell variant with chromophobe differentiation). RCC (a Clear cell variant with Chromophobe differentiation) is an unusual manifestation that arises from the left kidney's lower pole. In terms of diagnosis, staging, and treatment assessment, histopathological testing is crucial. As a result, for the diagnosis of such an unusually presented RCC, proper surgical and pathological correlation is essential. It's critical to acknowledge the presence of this clinical entity, which, though uncommon, may offer yet another
reason to pursue surgical or immunological treatment for metastatic renal cancer. The finding will inspire & motivate researchers to pursue immunologic and other disease-related research.

Keywords: CECT; histopathology; RCC.

1. INTRODUCTION

RCC leads to around 2%-4% of the newly diagnosed adult cancers [1]. RCC is the 7th utmost malignancy in the Western domain, with an ever-increasing frequency [2,3] and accounting for one-three percent of all malignant visceral neoplasms. RCC is the most deadly malignant urological tumor, with around 40% of patients dying due to disease progression. Currently, most RCCs are discovered by chance during imaging examinations, whether for urological or non-urological causes. Men make up the majority of RCC patients, accounting for two-thirds of all cases [4].

The typical signs were recognized as pain, abdominal mass, and hematuria. Fever, night sweats, weight loss, anemia, and hypercalcemia were all typical systemic symptoms in patients, and any of these symptoms may be part of the clinical syndrome. Also, with modern treatment, these characteristics appear to predict a worse outcome. An rise in RCC occurrence is because of extensive use of advanced imaging methods for other complaints that result in the discovery of a renal mass, which is commonly referred to as a small renal mass [5]. Due to its rising frequency, RCC has the highest death rate of all genitourinary malignancies. This tumor is heterogeneous, with various histological cell types and genetic, biochemical, and behavioral differences [6]. We present a case of an uncommon RCC clear cell with a chromophobe variant in this report.

2. CASE PRESENTATION

A 44-year-old female presented with the chief complaints of a lump in the abdomen for two months. Clinical findings revealed pain in the left flank for 15 days. The pain in the left lumbar region was progressive with hematuria.

CT scan with contrast content is called contrast-enhanced computed tomography (CECT). Contrast material is used during the CT scan, as the name suggests. CECT abdomen was suggestive of a markedly heterogeneous mass in the lower pole of the left kidney with areas of necrosis, cystic changes, and hemorrhage with adjacent calcifications.

RCC (Clear cell type of Chromophobe differentiation) is a rare symptom from the lower pole of the left kidney. Histopathological testing is critical for diagnosis, staging, and treatment evaluation. Consequently, proper surgical and pathological correlation is critical for the diagnosis of such an unusually presented RCC. As a result, various RCC variants should be considered for proper diagnosis.

When staining is positive, immunohistochemistry reports (IHC) are useful diagnostic tools. However, positive and negative staining of main immunomarkers is comparatively significant when using IHC to subtype renal cell carcinoma (RCC). The fixative used was formalin, and the research was done on Block Number(s): B/20/8941. It was discovered that without membrane attenuation, the results are negative. CK-7 and Vimentin were used to stain it. When stained for CK-7, the tumor displayed a score of “3+,” indicating that it is CK-7 positive. When stained for Vimentin, it revealed a score of “0,” indicating that the tumor is Vimentin negative.

The patient underwent nephrectomy without complications, and the removed mass was then sent for histological examination (HPE). Histopathological analysis of the post-nephrectomy specimen was performed. A spherical, brown nephrectomy specimen measuring 20 x 13.5 x 9 cm was found on gross inspection. Heterogeneous areas of necrosis and hemorrhage can be seen in the cut portion.

Two cell populations were noticed, one predominantly with large cells and centrally placed round nuclei with vesicular nucleoli arranged into tubules, clear granular cytoplasm admixed with small-sized cells with round nuclei, and scanty granular cytoplasm in sheet. Some golden yellow areas have been found. Neoplastic cells, well-differentiated with nuclear atypia, bizarre nuclei, giant cells, and pale eosinophilic cells with a perinuclear halo organized in solid sheets with intervening blood vessels diagnosed
as RCC were seen microscopically (Clear Cell variant with chromophobe differentiation).

3. DISCUSSION

RCC makes up two percent of all the tumors, and its prevalence is slowly increasing. It usually appears in late adulthood, and males are more likely than females to develop it [7].

The subjects might patient may experience problems viz. haematuria, pain, an abdominal mass, and systemic signs such as anemia & fever [8]. Patients with RCC can acquire the metastatic disease in twenty-thirty percent of cases, and twenty-fourty percent of patients with a nephrectomy for clinically localized illness can develop metastasis [9]. If the tumors cannot be removed entirely, the prognosis is typically poor. In the first three years, relapses occur 85 percent of the time [10]. Numerous studies have been mentioned in the past that describe metastatic renal cancer spontaneously regressing [8, 11].
Fig. 3. Gross specimen

Fig. 4. Chromophobe type-I

Fig. 5. Chromophobe type-II
Bumpus described the first case of metastatic renal cell cancer spontaneously regressing in 1928 [11]. Most of these cases are linked to the surgical exclusion of the primary tumor however, relapse can also happen after radiotherapy or embolization of the primary tumor [12].

In 1985, the chromophobe variant of RCC was mentioned for the first time [13]. Unlike conventional RCCs, which have a male preponderance, these are most typically discovered in the sixth decade of life and affect both men and women equally [14]. Almost 90% of ChRCCs are discovered in the early stages of the disease, i.e., stage 1 or 2. Renal vein invasion is also infrequent, occurring in only approximately five percent of cases. In chromophobe RCC, the rate of metastatic illness is lower, around 6-7 percent [15]. In a review of 28 patients, the liver (39%) and lungs (36%) were shown to be the most common metastatic sites for ChRCC, while the lungs (more than 50%) and bones were found to be the most common metastatic sites for RCC (33 percent [16]. Similar cases were reported by Bhalsod et al. [17] and Niveditha et al. [18].

Because of the unusual nature of the occurrence and the wide range of clinical situations under which spontaneous disease regression occurs,
there is no way to gain insight into the pathophysiologic process or identify possible candidates for regression.

4. CONCLUSION

Despite metastatic disease, RCC has a better prognosis than pRCC and a prognosis similar to ccRCC, with a median survival of around 29 months compared to 5.5 months in RCC [15]. The current evidence for the numerous available medications in advanced RCC is summarized here:

One inhibitors of mTOR
Two inhibitors of the c-Kit pathway
Three inhibitors of tyrosine kinase
4 Alpha-interferon.
5 Immune checkpoint inhibitors.
6 Interleukin-2 (IL-2, Proleukin)

It’s critical to acknowledge the presence of this clinical entity, which, though uncommon, may offer yet another reason to pursue surgical or immunological treatment for metastatic renal cancer. The finding will inspire & motivate researchers to pursue immunologic and other disease-related research. Chromophobe carcinoma is a type of RCC that is relatively uncommon. We’re presenting this instance because it’s a rare occurrence. Clinically and histopathologically, the ChRCC is a separate entity. On microscopy, it’s typically difficult to tell the difference between oncocytomas and clear cell RCCs. Histopathologists must recognize and identify ChRCCs earlier, since they have a better prognosis and have longer survival rates than conventional RCCs.

CONSENT AND ETHICAL APPROVAL

As per university standard guideline, participant consent and ethical approval have been collected and preserved by the authors

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
3. Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60:615–2.
4. Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiologia Brasileira. 2015;48(3):166-74.
5. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
6. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
7. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
8. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
9. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
10. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
11. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
12. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
13. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
14. Dutcher JP. Update on the biology and management of renal cell carcinoma. J Investig Med. 2019;67(1):1-0.
disease. 8th ed. Saunders Elsevier. 2010:963-967.

15. Cheville JC, Lohse CM, Zincke H, Weaver H, Blute AL, Michael L. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.

16. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 2002; 20:2376–81.

17. Bhalsod HD, Khan IA. Chromophobe variant of renal cell carcinoma - A rare case report. Medical Science. 2021;25 (110):812–5.

18. Niveditha S, Abhijit Dhale, Meenakshi Yeola. Renal Cell Carcinoma with Tumour Thrombus Adherent to Inferior Vena Caval Wall: A Case Report. Medical Science. 2020;24(106):4014–18.